Cosimo Prantera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cosimo Prantera has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Anna Kohn
Department of Gastroenterology, San Camillo-Forlanini Hospital, Rome, Italy
4 shared publications - Mario Cottone
University of Palermo, Palermo, Italy
4 shared publications - Angelo Viscido
Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L’Aquila, Piazza S. Tommasi, 1, Coppito, 67100 L’Aquila, Italy
3 shared publications Herbert Lochs
Rektorat Medizinische Universität Innsbruck, Innsbruck, Austria
3 shared publicationsMarina Rizzi
Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
3 shared publications- Massimo Campieri
University of Bologna
3 shared publications
Latest Publications
- 21 May 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (12) , 1435
Letter: budesonide MMX for ulcerative colitis?
- 21 May 2014
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 39 (12) , 1435
Letter: budesonide MMX for ulcerative colitis?
- 3 February 2014
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 15 (6) , 741-743
Budesonide multi-matrix system formulation for treating ulcerative colitis
Budesonide is a corticosteroid characterized by high topical activity and low systemic effect associated with fewer glucocorticoid-related adverse events than conventional steroids. Differently from Crohn's disease, no evidence suggests that oral budesonide is effective for the induction of remission of ulcerative colitis (UC). Budesonide multi-matrix (MMX) system is a new oral preparation that, by employing a MMX, provides the release of the drug throughout the entire colon. Its efficacy in inducing UC remission, at a dose of 9 mg, is based on some recent trials. However, in two studies the absolute differences between budesonide MMX and placebo were much lower than the rate of success reported in previous trials with mesalazines. In addition, the therapeutic advantage of budesonide MMX 9 mg over 5-aminosalicylic acid (5-ASA) showed by one study, and the advantage of budesonide MMX over budesonide reported in the other study, was only 5.8 and 4.8%, respectively. The evidence supporting the use of budesonide MMX at a dose of 6 mg for maintenance is weak. Therefore, the effective dosage should be 9 mg also in maintenance, but not for > 4 - 6 months, because a prolonged treatment has showed to increase the rate of side effects.
- 3 February 2014
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 15 (6) , 741-743
Budesonide multi-matrix system formulation for treating ulcerative colitis
Budesonide is a corticosteroid characterized by high topical activity and low systemic effect associated with fewer glucocorticoid-related adverse events than conventional steroids. Differently from Crohn's disease, no evidence suggests that oral budesonide is effective for the induction of remission of ulcerative colitis (UC). Budesonide multi-matrix (MMX) system is a new oral preparation that, by employing a MMX, provides the release of the drug throughout the entire colon. Its efficacy in inducing UC remission, at a dose of 9 mg, is based on some recent trials. However, in two studies the absolute differences between budesonide MMX and placebo were much lower than the rate of success reported in previous trials with mesalazines. In addition, the therapeutic advantage of budesonide MMX 9 mg over 5-aminosalicylic acid (5-ASA) showed by one study, and the advantage of budesonide MMX over budesonide reported in the other study, was only 5.8 and 4.8%, respectively. The evidence supporting the use of budesonide MMX at a dose of 6 mg for maintenance is weak. Therefore, the effective dosage should be 9 mg also in maintenance, but not for > 4 - 6 months, because a prolonged treatment has showed to increase the rate of side effects.
- 28 February 2013
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 6 (2) , 137-156
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroid-based drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn’s disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn’s disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.
- 28 February 2013
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 6 (2) , 137-156
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroid-based drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn’s disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn’s disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.
- Open Access
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (42) , 7487-8
Rifaximin and Crohn's disease.
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic involvement seemed to be associated with a significant higher efficacy of rifaximin-EIR 800 mg twice daily. Early-stage disease is generally considered as the more easily treatable phase of CD, and the better response to rifaximin in Crohn's colitis is in accordance with the high concentration of bacteria in the colon. In addition, patients with C reactive protein level > 5 mg/L achieved remission more significantly than patients with normal values, thus suggesting that the symptoms were probably caused by inflammation instead of by non-inflammatory causes. We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics.
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (42) , 7487-8
Open AccessRifaximin and Crohn's disease.
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic involvement seemed to be associated with a significant higher efficacy of rifaximin-EIR 800 mg twice daily. Early-stage disease is generally considered as the more easily treatable phase of CD, and the better response to rifaximin in Crohn's colitis is in accordance with the high concentration of bacteria in the colon. In addition, patients with C reactive protein level > 5 mg/L achieved remission more significantly than patients with normal values, thus suggesting that the symptoms were probably caused by inflammation instead of by non-inflammatory causes. We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics.
- 1 May 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (5) , 369-374
Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study
- 1 May 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (5) , 369-374
Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study
- 1 March 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (3) , 473-481.e4
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- 1 March 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (3) , 473-481.e4
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- 30 June 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (6) , 459-464
Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial
- 30 June 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (6) , 459-464
Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
A New Extended Intestinal Release Formulation of Rifaximin, 400 mg Tablets, for the Treatment of Moderately Active Crohn's Disease
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
A New Extended Intestinal Release Formulation of Rifaximin, 400 mg Tablets, for the Treatment of Moderately Active Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
W1268 The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
W1268 The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -685-685
W1257 Infliximab for Severe Ulcerative Colitis: Short-Term and One Year Outcome of Three Dose Regimen. An Italian Multicentre Open-Label Study
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -685-685
W1257 Infliximab for Severe Ulcerative Colitis: Short-Term and One Year Outcome of Three Dose Regimen. An Italian Multicentre Open-Label Study